Podcast Episodes

Back to Search
Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B
Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B

Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its…

2 months, 1 week ago

Short Long
View Episode
Pharmaceutical Executive Daily: FDA Approves Zanvastro
Pharmaceutical Executive Daily: FDA Approves Zanvastro

Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical Executive’s weekly biotech roundu…

2 months, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Ultragenyx's Apazunersen Fails Phase III Trial
Pharmaceutical Executive Daily: Ultragenyx's Apazunersen Fails Phase III Trial

Ultragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research talks through the mechani…

2 months, 2 weeks ago

Short Long
View Episode
The Ron Lanton Report: What Are We Doing This All For?
The Ron Lanton Report: What Are We Doing This All For?

Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, joins Ron Lanton to argue that biopharmaceutical policy …

2 months, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials
Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials

Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials over safety concerns, a dealmaking roundup covers Alteogen's licensing deal with Nova…

2 months, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing
Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA flu vaccine into Phase I…

2 months, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences
Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer immunotherapy Cevumeran, and P…

2 months, 2 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major biopharma deals, and Isr…

2 months, 3 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: President Trump Planning New Medicaid Drug-Pricing Deals
Pharmaceutical Executive Daily: President Trump Planning New Medicaid Drug-Pricing Deals

Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs make it to market, and t…

2 months, 3 weeks ago

Short Long
View Episode
Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera
Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera

A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major licensing deals with SK…

2 months, 3 weeks ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us